

RESEARCH COMMUNICATION

Overexpression of Cyclin L2 Inhibits Growth and Enhances Chemosensitivity in Human Gastric Cancer Cells

Hong-Li Li[&], Ding-Zhi Huang[&], Ting Deng, Li-Kun Zhou, Xia Wang, Ming Bai, Yi Ba^{*}

Abstract

Cyclin L2 is a novel member of the cyclin family, recently implicated in the regulation of cell cycle progression and/or transcriptional regulation. The present study was undertaken to investigate the effects of overexpression on tumor cell growth and chemosensitivity in human gastric cells *in vitro*. Cyclin L2 was transfected into human gastric cancer cell line BCG823 and expressed with a mammalian expression vector pcDNA3.1. The effects and mechanisms of cyclin L2 on cell growth, cell cycling and apoptosis were studied. Compared to control vectors, overexpression of cyclin L2 inhibited the growth of BCG823 cells and enhance their chemosensitivity to fluorouracil, docetaxel and cisplatin. The anti-proliferative effects of cyclin L2 could be due to G0/G1 arrest and apoptosis. Cyclin L2 induced G0/G1 arrest and apoptosis involved upregulation of caspase-3 and down regulation Bcl-2 and survivin. The results indicated that overexpression of cyclin L2 protein may promote efficient growth inhibition and enhance chemosensitivity to chemotherapeutic agents in human gastric cancer cells by inducing G0/G1 cell cycle arrest and apoptosis.

Keywords: Cyclin L2 - gastric cancer - apoptosis - cell cycle - chemosensitivity

Asian Pacific J Cancer Prev, **13**, 1425-1430

Introduction

Gastric cancer is reputed to be one of the most frequent and lethal malignancies in the world, particularly in Eastern Asia, Eastern Europe, and South America (Jemal et al., 2011). Although the range of therapeutic strategies available for treatment of this malady have improved over the past decades, however, the median survival time for advanced gastric cancer patients still appears to remain around seven to nine months (Wagner et al., 2006). Environmental and genetic factors are both important in gastric carcinogenesis (Wagner et al., 2006; Jemal et al., 2011). In recent years, knowledge about the molecular features of gastric carcinoma has increased rapidly. The development of novel strategies for inhibiting tumor cell growth and enhancing chemosensitivity are the focus of much medical research (Bang et al., 2010).

Cyclins are key regulatory proteins that complex with and activate cyclin-dependent kinase (CDK) subunits, playing pivotal roles in the regulation of cell cycle progression (Duman-Scheel et al., 2002). Cyclins may be currently classified into two major groups, seemingly reflecting their functions. The cell cycle regulator cyclins, composed primarily of cyclin A, B, D1, D3, E, and F, function with their CDK partners including CDK1, -2, -3, and -4 to regulate promotion of the cell cycle. The transcription regulator cyclins, which include cyclin C, H,

K, L1, T1 and T2, work together with CDK7, -8 and -9 and tend to play roles in transcriptional regulation (Yang et al., 2004). Among the cyclin molecules, previous studies have implicated some cyclins in apoptosis and growth inhibition of tumor cells, such as cyclin K and cyclin G1 both induce a G1-phase arrest in mammalian cells (Mori et al., 2002). It has also been shown that cyclin L1 is highly expressed in head and neck cancer. The elevated level of expression of cyclin L1 usually indicates a better prognosis (Redon et al., 2002). Cyclin L2 is one novel member of cyclin family and has been observed to promote apoptosis *in vitro* studies with human cancer cell lines (Graaf et al., 2004; Yang et al., 2004; Li et al., 2007). Although the physiological roles of cyclin/CDK pairs are intensively studied, the mechanisms of cyclin L2 in regulating cell cycle progression or apoptosis are still largely unknown. Such knowledge may help for better understanding and potentially better treatment strategies in cancer research and management. In this study, gastric carcinoma cells were transfected with cyclin L2 to observe the effects on growth and chemosensitivity to fluorouracil, Docetaxel and cisplatin.

Materials and Methods

Cell lines

BCG823 (human gastric cancer cell lines) and A549

Department of Gastrointestinal Oncology, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China [&]Equal contributors ^{*}For correspondence: dryiba@gmail.com, baayi@163.com

(human lung adenocarcinoma cell lines) were obtained from the American Type Culture Collection (ATCC, Baltimore, USA, except for HT-29 (human hepatocellular carcinoma cell lines). Cells were maintained in RPMI 1640 medium containing 100 U/ml penicillin, 100 mg/ml streptomycin and 10% fetal bovine serum (Gibco, UK) at 37 °C in a 5% CO₂ humidified atmosphere.

Mammalian expression vector and cell transfection

The full-length coding region of human cyclin L2 was cloned into the myc-6His-tagged expression vector pcDNA3.1/Myc-His (pCCNL2) and the antisense construct pCCNL2-AS or pcDNA3.1 mock vector were all kindly provided by Prof. Cao Xue-Tao (Institute of Immunology, Second Military Medical University, Shanghai, China). The pCCNL2, pCCNL2-AS, or pcDNA3.1 mock vectors were transfected using liposome-mediated LipofectAMINE reagent (Invitrogen, USA) into A549 cells according to the manufacture's instructions and screened under 500 µg/ml G418 (Calbiochem, USA) for 3-5 weeks. Cell clones of stably transfected cells were obtained by the limited dilution method.

Cell proliferation assays

Cell proliferation of transiently transfected BCG823 cells were assessed by cell viability using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) dye reduction assay. To initiate experiment, cells were seeded at 5×10³ cells/ml in 96-well plates and harvested at 0, 24, 48, 72 and 96 hour after transient transfection of pCCNL2, pCCNL2-AS, or pcDNA3.1 mock vector, respectively. One hundred µl of the culture medium containing MTT reagent (1 mg/ml) was added into the wells and incubated for additional 4 hours. Then the medium was removed and 100 µl of Me2SO (Sigma, USA) was added to each well. The plates were shaken at room temperature for 10 minutes. Cellular viability was determined by measuring the absorbance of the converted dye at a wavelength of 570 nm.

Flow cytometry assay

After transient transfection of pCCNL2, pCCNL2-AS, or pcDNA3.1 mock vectors for 24, 48, 72 hours, respectively, BCG823 cells were harvested and fixed overnight with 70% ethanol at 4 °C, followed by resuspension in 500 µl of phosphate buffered solution (PBS). After the addition of 10 µl RNase (10 mg/ml), cells were incubated for 30 minutes at 37 °C and stained with 10 ml propidium iodide (1 mg/ml). The cells suspension was analyzed on a Coulter Epics Elite flow cytometer (Beckman-Coulter, Miami, USA). Cell cycle analysis was performed with the Multicycle System (Phoenix Flow Systems, USA).

Chemotherapy-induced cytotoxicity

BCG823 cells were seeded in a 96-well plate at a concentration of 5×10³ cells/well for 16 h and then transfected with pCCNL2, pCCNL2-AS, or pcDNA3.1 mock vectors for 24 hours respectively. Cells were incubated with medium contain chemotherapeutic agents in different concentrations (fluorouracil at the

concentration of 0.625, 2.5, 10, 40, 120 mg/L, docetaxel at the concentration of 10, 50, 100, 500, 1000 nmol/L, or cisplatin at the concentration of 0.125, 0.5, 2, 8, 32 mg/L, respectively) for 48 h. Cell variability was examined by MTT assay at 570 nm (OD readings). The suppression rate was calculated using the formula: Suppression rate = (1-OD_{treatment}/OD_{control}) × 100%.

Protein extraction

BCG823 cells were plated in 6-well plates and transient transfection of pCCNL2, pCCNL2-AS, or pcDNA3.1 mock vector for 24 hours, respectively. Floating and adherent cells were harvested and combined. Cells were lysed with RIPA lysis buffer containing protease inhibitor Cocktail II (Upstate, Lake Placid, NY, USA). The samples were reduced at 70 °C for 10 minutes, and cooled on ice before being stored at -80 °C.

Western blot

Western blot was performed as described previously (Barton et al., 2005). Briefly, proteins (20 µg/lane) were separated by 12% SDS-PAGE. The SeeBlue prestained standard (Invitrogen, USA) was used to determine protein size. After electrophoresis, proteins were transferred onto polyvinylidene difluoride (PVDF) membrane (GE Health, USA) using the XCell II Blot Module (Invitrogen, USA) for 1.5 hours at 30 V. The membrane was blocked with 5% nonfat milk in PBST (PBS, 0.1% Tween 20) for 1 hour. After being washed three times with PBST, the membrane was then incubated with primary antibody diluted in PBST, 5% nonfat dry milk powder at room temperature with agitation for 1 hour. Blots were then probed with horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, USA), and protein bands were detected using the enhanced chemiluminescence (ECL) system (Cell Signaling, USA) and quantified by densitometry using Bio-Rad Quantity One software (Bio-Rad, Hercules, USA).

Antibodies

All of the antibodies, excluding Bcl-2 (Cell signaling), were commercially obtained from Santa Cruz (Berkeley, USA). The sequence of cyclin L2 cDNA was sub-cloned inframe into pGEX-4T3 (Amersham Biosciences, USA) for glutathione S-transferase (GST) fusion protein expression. GST-CCNL2 fusion protein expressed in Escherichia coli BL21 (Stratagene, CAN) was affinity-purified with glutathione-sepharose 4B (Amersham Biosciences) and eluted in 10 mmol/L reduced glutathione. An antiserum specific for the long form of cyclin L2 was raised by immunization of rabbits with a peptide corresponding to amino acids 437-448 within the C-terminal serine/arginine-rich (RS) domain.

Statistical analysis

Values were expressed as mean ± standard deviation (SD). Results were evaluated by analysis of variance (ANOVA) using SPSS 11.0 software (SPSS, Chicago, USA), unless otherwise specified. A P value < 0.05 was considered to represent statistical significance.




Figure 1. Cyclin L2 Expression in Vitro and Effect on the Growth of BCG823 Cells. (A) Human cyclin L2 was higher expressed in human gastric cancer cell lines BCG823 and human hepatocellular carcinoma cell lines HT29, but lower in human lung adenocarcinoma cell lines A549. (B) The protein of cyclin L2 expressed by BCG823 cells which transfected pCCNL2 was further verified using western blot. (C) Cell proliferation of transiently transfected BCG823 cells was determined by MTT. The results represent means of three independent experiments. Asterisk indicates $P < 0.05$ compared with the control




Figure 2. Effect of Combination of Cyclin L2 and Chemotherapeutic Agents on BCG823 Cells Proliferation by MTT in Vitro. Overexpression of cyclin L2 enhanced the chemosensitivity of human gastric cancer cell lines BCG 823 cells to fluorouracil (A), docetaxel (B) and cisplatin (C). The results represent means of three independent experiments. Asterisk indicates $P < 0.05$ compared with the control

Results

Transfection of pCCNL2 into BCG823 cells

Human cyclin L2 is expressed widely in normal human tissues and tumors cells. We have detected the expression of human cyclin L2 in three human solid tumor cell lines. As shown in Figure 1A, cyclin L2 is expressed a relatively higher level in human gastric cancer cell lines BCG823 and human hepatocellular carcinoma cell lines HT-29, it almost couldn't detect in human lung adenocarcinoma cell lines A549 by western blotting. To analyze the




Figure 3. Analysis of Cell-cycle arrest and Apoptosis in Combination of Cyclin L2 and Chemotherapeutic Agents on BCG 823 Cells. (A) After transfecting with pCCNL2, pCCNL2-AS or pCDNA3.1, cells were treated with Fluorouracil, Docetaxel or Cisplatin in different concentrations, respectively. (B) Effect of CCNL2 overexpression on caspas-3, Bcl-2 and survivin. BCG 823 cells were transfected with pCDNA3.1 (mock), pCCNL2, or pCCNL2-AS, respectively, with parental cells as control. Whole cells lysates were analyzed for caspase-3, Bcl-2 and survivin by Western blot. b-actin was used as a loading control. Representative blots from three independent experiments are shown

efficiency of pCDNA3.1 gene delivery system transfected into cells, proliferation of BCG823 cells were assessed by immunofluorescence assay after transfection of the pCDNA 3.1/GFP for 1 hour. Compared with the control cells, distinct green signal from fluorescein isothiocyanate (FITC) could be observed after the cells transfected pCDNA3.1/GFP for 4 hour (data not shown). The protein cyclin L2 was further verified using Western blot (Figure 1B). Human cyclin L2 protein was expressed in BCG823 cells at higher levels after transfected pCCNL2.

Anti-proliferative effects of cyclin L2 on BCG 823 cells

Addressing whether overexpression of human cyclin L2 would affect the growth of BCG823 cells may help understanding the molecular mechanisms of the cellular malignant phenotype, and provide insights of invasion and metastasis of tumor cells. Proliferation of BCG823 cells transiently transfected with pCCNL2 were analyzed by MTT assay. AS shown in Figure 1C, the proliferation of BCG823 cells transfected with pCCNL2 were inhibited compared with that of mock vector-transfected cell or parental BCG823 cells ($P < 0.05$), especially in cells transfected with pCCNL2-AS ($P < 0.01$). The results suggested that overexpression of human cyclin L2 has inhibited growth of human gastric cancer cells in vitro.

Effect of cyclin L2 or chemotherapeutic agents on BCG823 cell proliferation

Next we assessed whether overexpression of cyclin L2 affect chemosensitivity of Fluorouracil, Docetaxel or Cisplatin to BCG823 cells. After transfecting with pCCNL2, pCCNL2-AS or pCDNA3.1, cells were treated

Table 1. Cyclin L2 Delays G0/G1 Progression and Induces Apoptosis

Groups	G0/G1 (%)	S (%)	G2/M (%)	Apoptosis (%)
Parental	58.1±5.12	32.5±5.52	9.40±0.74	0.62±0.21
Mock	60.6±2.50	32.5±1.06	6.99±1.78	2.01±0.63
CCNL2	72.0±5.75*	17.2±5.45	10.8±3.25	7.34±0.51 [§]
CCNL-AS	18.0±0.48	80.5±3.04	1.48±0.41	0.19±0.06

Cell cycle and apoptosis rates of BCG 823 cells were evaluated by flow cytometry as Described in "Materials and Methods"; Data were represented as mean±SD of three independent experiments; *P < 0.05, [§]P < 0.01

Table 2. Cyclin L2 Enhance Chemotherapeutic Sensitivity

Groups	G0/G1 (%)	S (%)	G2/M (%)	Apoptosis (%)
Cisplatin				
Parental	56.3±2.86	32.2±1.53	11.6±2.84	11.5±1.60
Mock	56.0±2.05	33.7±7.01	10.4±2.00	13.5±2.34
CCNL2	67.6±2.65*	21.4±1.69	11.1±1.68	44.2±5.09 [§]
CCNL-AS	56.2±1.73	38.4±1.75	5.46±1.06	8.48±2.57
Fluorouracil				
Parental	56.6±1.34	34.3±2.63	9.13±0.71	13.1±1.06
Mock	57.3±1.41	35.2±1.71	7.54±0.71	14.4±2.85
CCNL2	68.1±1.23*	0.72±0.21	17.7±2.32	35.3±6.24 [§]
CCNL-AS	46.1±1.34	38.0±2.83	15.9±1.48	7.69±1.29
Docetaxel				
Parental	4.12±0.78	36.9±1.92	59.0±2.14	8.03±1.89
Mock	2.18±1.27	34.8±2.14	63.0±3.13	9.28±2.29
CCNL2	44.8±1.41*	17.3±2.71	37.9±1.71	29.7±9.71 [§]
CCNL-AS	5.33±0.64	22.1±2.01	72.6±3.64	4.52±1.21

Cell cycle and apoptosis rates of BCG 823 cells to cyclin L2 combination with therapeutic agents were evaluated by flow cytometry as Described in "Materials and Methods"; Data were represented as mean±SD of three independent experiments; *P < 0.05, [§]P < 0.01

with Fluorouracil (Figure 2A), Docetaxel (Figure 2B) or Cisplatin (Figure 2C) in different concentrations, respectively. We found that transfection with pCCNL2 enhances the cytotoxicity of three chemotherapeutic agents, respectively. The inhibition rate curve of pCCNL2 moved up compared with parental or mock groups (Figure 3). However, the curve of pCCNL2-AS moved down compared with control groups. For example, as the concentration of docetaxel in 0.1 mol/L, the inhibition rate of parental and mock groups was 32% ± 9.8% and 33.8% ± 8.9%, respectively, significantly lower than those in pCCNL2 44.6%±10.8%. However, its was 23.3% ± 6.8% in pCCNL2-AS groups, significantly lower than that in control groups. These data indicated that overexpression of cyclin L2 could enhance chemosensitivity in gastric carcinoma cells in vitro.

Cyclin L2 treatment with chemotherapeutic agents induces cell cycle arrest and apoptosis

According to the results of MTT assay, we further analyzed the effect of overexpression of CCNL2 on cell cycle and apoptosis by flow cytometry. BCG 823 cells were transiently transfected with pCCNL2 and compared with that of mock vector or parental BCG 823 cells. BCG823 cells transfected with pCCNL2-AS were used to eliminate endogenous CCNL2. After transfected

with pCCNL2 for 24 hours, cell cycle analysis revealed an increase of G0/G1 phase and an evident apoptosis by comparison to the control cells (Table 1).

Next we assessed whether overexpression of cyclin L2 affect on chemotherapeutic agents mediated apoptosis. After transfecting with pCCNL2, pCCNL2-AS or pcDNA3.1, cells were treated with Fluorouracil, Docetaxel or Cisplatin in different concentrations, respectively. We found that BCG823 cells accumulated in the G0/G1 phase and after transfected with pCCNL2 for 24 hours, in contrast to cells transfected with mock vector or parental cells (Figure 3A, Table 2). In addition, compared with control group cells, its significant increases in the proportion of apoptosis cells which transfected pCCNL2 and then exposed to chemotherapeutic agents, respectively (Figure 3A, Table 2).

Overexpression of cyclin L2 up-regulates the expression of caspases-3 and down-regulates the expression of Bcl-2 and survivin

It is well known that cell cycle arrest and apoptosis are associated with activation of caspases and anti-apoptosis proteins. To examine the molecular mechanisms underlying the G0/G1 phase arrest and apoptosis in BCG823 cells induced by overexpressed cyclin L2, we examined the levels of the apoptosis protein Bcl-2 and survivin by Western blot analysis. As shown in Fig 3B, transient expression of cyclin L2 induced an increase in caspase-3 (2- and 3-fold, respectively) in BCG823 cells 24 hours post-transfection compared with pCCNL2-AS and mock vector-transfected, or parental BCG823 cells. Conversely, Bcl-2 and survivin expression were down-regulated in BCG823 cells overexpression of human cyclin L2. These results demonstrate that overexpression of human cyclin L2 modulates the expression of critical apoptotic factors, leading to cell cycle arrest and apoptosis.

Discussion

Cyclins have been shown to play an important role in the regulation of the cell cycle. Certain cyclins and their pairs proteins, CDKs, are recognized to have critical roles in the regulation of the transcription (Graaf et al., 2004; Egloff et al., 2006). Cyclin L2 and the closely related isoform, cyclin L1 (originally named cyclin L) differ from all other members of the cyclin family by the presence of a C-terminal RS domain. The RS domain is a hallmark of many proteins involved in pre-mRNA progression of the cell cycle and the signal transduction of apoptosis and oncogenesis (Graaf et al., 2004; Yang et al., 2004; Loyer et al., 2008). In the present study, we observed that overexpression of human cyclin L2 have direct anti-proliferative effects on BCG823 cells, and also able to induce cellular apoptosis in vitro. Elucidating the mechanism in specific cell type is important for understanding the growth regulation in particular tumor type. Therefore, cell cycle progression was further analyzed by flow cytometry in this study. Both G0/G1 phase arrest and apoptosis were found to contribute to cyclin L2 mediated growth suppression in BCG823 cells, which is consistent with the cell cycle and apoptosis

analysis in human hepatocellular carcinoma SMMC7721 cell lines and human lung carcinoma A549 cell lines (Yang et al., 2004; Li et al., 2007).

Systemic chemotherapy is widely accepted as palliative treatment for patients with unresectable or metastatic gastric cancer (Wagner et al., 2006; Ajani et al., 2007; Bang et al., 2010). Despite some advances in treatment of advanced gastric cancer, there is still no a satisfactory regimen which could be accepted as standard regimen for gastric cancer (Wagner et al., 2006; Ohtsu et al., 2011). Chemotherapeutic drug resistance is a fundamental problem in cancer management, responsible for most cases of treatment failure in patients with metastatic cancer (Swanton et al., 2007). An emerging understanding of the molecular pathways that characterize cell growth, cell cycle, apoptosis, angiogenesis and invasion has provided novel targets in cancer therapy (Shapiro et al., 2006; Ohtsu et al., 2011). Accordingly, combining various chemotherapeutic agents with noncytotoxic agents is of great importance for improving the efficacy of chemotherapeutics and overcoming resistance to cytotoxic drugs (Taberero et al., 2005). Some previous studies reported that combined treatment with cyclin-dependent kinase pathway inhibitors and chemotherapeutic agents for cancer treatment resulted in additive therapeutic effects (Shapiro, 2006; Lazzarini et al., 2008). In the present study, we firstly demonstrated that combination of cyclin L2 and chemotherapeutic agents such as fluorouracil, docetaxel or cisplatin resulted in enhanced cell growth inhibition in BCG823 cells in vitro. Cell cycle analysis revealed that combination cyclin L2 with conventional chemotherapeutic agents enhanced the arrest of BCG823 cells in G0/G1 phase and an evident apoptosis. The current studies directly support the incorporation of cyclin L2 into chemotherapeutic drugs treatment regimens as a means to improve the chemosensitivity of each drug. Despite there is still an urgent need to develop novel drugs that can target different sites and pathway of the cell cycle while avoiding drug induced cytotoxicity in the clinical applications, the data should be further validated in animal model in future.

As we known, fluorouracil interferes with DNA synthesis by blocking thymidylates, an enzyme involved in the conversion of deoxyuridylic acid to thymidylic acid (Li et al., 2008). Docetaxel can impair the dynamic of microtubules, promote their polymerization, and arrest the cells in mitosis by binding to the β subunit of tubulin (Hernandez-Vargas et al., 2007). Cisplatin can covalently bond to proteins, RNA, and especially DNA, forming DNA cross-linking and intrastrand N-7 adducts (Reedijk et al., 1985). To investigate the mechanisms of cyclin L2-induced cell cycle arrest, we evaluated the expression of apoptosis-related protein in BCG823 cells. Caspases-3 is one of key effector molecules that are required in most apoptotic pathway (Alenzi, et al., 2010). Overexpression of cyclin L2 induced an increase in caspase-3 in BCG823 cells 24 hours post-transfection compared with mock vector-transfected, or parental BCG823 cells. Conversely, Bcl-2 and survivin expression were down-regulated in BCG823 cells which overexpressed human cyclin L2. These data suggested that cyclin L2 might activate caspase-3 cascade by suppressing antiapoptotic protein

levels. These different targeted sites and pathways of the cell cycle from the chemotherapeutic agents such as fluorouracil, docetaxel or cisplatin might be partly causes of cyclin L2 enhanced chemosensitivity in human gastric cancer cells.

In summary, this study demonstrates that overexpression of cyclin L2 could inhibit the growth of human gastric adenocarcinoma BCG823 cells and enhance the chemosensitivity to fluorouracil, docetaxel and cisplatin in vitro. These effects could be due to cyclin L2 induced G0/G1 arrest and apoptosis involved upregulation of caspase-3 and down regulation Bcl-2 and survivin. It seems to be reasonable to perform further studies to identify the therapeutic benefit of cyclin L2 in animal model with solid tumors, and also to evaluate whether the combination of cyclin L2 with cytotoxic agents enhances antitumor effect in vivo.

Acknowledgements

The author(s) declare that they have no competing interests.

References

- Ajani JA, Moiseyenko VM, Tjulandin S, et al (2007). Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. *J Clin Oncol*, **25**, 3205-9.
- Alenzi FQ, Lotfy M, Wyse R (2010). Swords of cell death: caspase activation and regulation. *Asian Pac J Cancer Prev*, **11**, 271-80.
- Bang YJ, Van Cutsem E, Feyereislova A, et al (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. *The Lancet*, **376**, 687-97.
- Barton C, Davies D, Balkwill F, et al (2005). Involvement of both intrinsic and extrinsic pathways in IFN-gamma-induced apoptosis that are enhanced with cisplatin. *Eur J Cancer*, **41**, 1474-86.
- Duman-Scheel M, Weng L, Xin S, et al (2002). Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. *Nature*, **417**, 299 -304.
- Egloff AM, Vella LA, Finn OJ (2006). Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. *Cancer Res*, **66**, 6-9.
- Graaf K, Hekerman P, Spelte O, et al (2004). Characterization of cyclin L2, a novel cyclin with an arginine/serine-rich domain phosphorylation by DYRK1A and colocalization with splicine factors. *J Biol Chem*, **279**, 4612-24.
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. *Ca Cancer J Clin*, **6**, 69-90.
- Lazzarini R, Moretti S, Orecchia S, et al (2008). Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma. *Clin Cancer Res*, **14**, 5099-107.
- Li HL, Wang TS, Li XY, et al (2007). Overexpression of cyclin L2 induces apoptosis and cell-cycle arrest in human lung cancer cells. *Chin Med J*, **120**, 905-9.
- Li S, Wang A, Jiang W, et al (2008). Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. *BMC Cancer*, **8**, 103-11.

- Loyer P, Trembley JH, Grenet JA, et al (2008). Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection. *J Biol Chem*, **283**, 7721-32.
- Mori T, Anazawa Y, Matsui K, et al (2002). Cyclin K as a direct transcriptional target of the p53 tumor suppressor. *Neoplasia*, **4**, 268 -74.
- Ohtsu A, Shah MA, Van Cutsem E, et al (2011). Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. *J Clin Oncol*, **29**, 3968-76.
- Redon R, Hussenet T, Bour G, et al (2002). Amplicon mapping and transcriptional analysis pinpoint cyclin L as a candidate oncogene in head and neck cancer. *Cancer Res*, **62**, 6211-7.
- Reedijk J, Lohman PH (1985). Cisplatin: synthesis, antitumour activity and mechanism of action. *Pharm Weekbl Sci*, **7**, 173-80.
- Shapiro GI (2006). Cyclin-dependent kinase pathways as targets for cancer treatment. *J Clin Oncol*, **24**, 1770-83.
- Swanton C, Marani M, Pardo O, et al (2007). Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. *Cancer Cell*, **11**, 498-512.
- Tabernero J, Macarulla T, Ramos FJ, et al (2005). Novel targeted therapies in the treatment of gastric and esophageal cancer. *Ann Oncol*, **16**, 1740-8.
- Wagner AD, Grothe W, Haerting J, et al (2006). Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. *J Clin Oncol*, **24**, 2903-9.
- Yang L, Li N, Wang C, et al (2004). Cyclin L2, a novel RNA polymerase II-associated cyclin, is involved in pre-mRNA splicing and induces apoptosis of human hepatocellular carcinoma cells. *J Biol Chem*, **279**, 11639 -48.